All Articles
The following clinical trials represent a selection of key studies currently recruiting patients with gynecologic cancers for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to one of these trials. Read More ›
Welcome to this virtual clinical utility study. It's being done to assess use of a novel biomarker in the treatment decision-making for immunotherapy-eligible first-line advanced stage non-small cell lung cancer patients. Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses pivotal presentations from ASCO 2023 focused on metastatic colorectal cancer (mCRC). Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses the trends and outcomes of older patients compared to younger patients who received 1L chemotherapy for mCRC. Read More ›
Dr. Sardesai, medical oncologist at The Ohio State University in Columbus, OH, discusses key considerations relating to the approval of ORSERDU (elacestrant), including appropriate patient selection, the clinical relevance of ESR1 mutations, and key takeaways from the EMERALD trial. Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he describes the outcomes and study design of clinical trials evaluating targeted therapeutic options for patients with mCRC. Read More ›
Peer-to-peer (PTP) support is an important aspect of nonprofessional patient care that improves cancer-specific quality of life. However, PTP research is sorely lacking, with very few randomized controlled trials being conducted in this space, as well as a lack of standardized quality parameters for what constitutes successful and efficient PTP support, according to newly published research. Read More ›
Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, Director, Yale Cancer Center, and Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven, CT, and ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes. Read More ›
At the 10th Annual Cholangiocarcinoma Foundation Conference, Rachna Shroff, MD, MS, Chief, Gastrointestinal Medical Oncology, and Director, Clinical Trials Office, University of Arizona Cancer Center, Tucson, and Madhulika Eluri, MD, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, debated whether chemotherapy remains the backbone for cholangiocarcinoma (CCA) treatment or if it is time to move away from this therapeutic strategy. Read More ›
Sarcoma is a general term used to describe a broad group of rare malignancies that develop in the body’s bone and connective tissue, such as fat, muscle, nerves, blood vessels, and the tissue that surrounds bones and joints. It is frequently referred to as the “forgotten cancer” because it comprises a very small percentage of all adult cancers. Read More ›